
Bexarotene
Bexarotene gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or…
Find the latest prescription medication package inserts and labels directly from the approved FDA repository of SPL records, keep up with an RSS feed of all FDA prescription medication updates, or follow a company-specific feed of prescription medication updates from an individual manufacturer.
Bexarotene gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or…
KISQALI is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer…
Mesalamine extended-release capsules are indicated for the induction of remission and for the treatment of adult patients with mildly to moderately active ulcerative colitis…
The KISQALI FEMARA CO-PACK is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor…
For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy…
See more of the latest, organized alphabetically…
As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.
Terms of Use | Copyright © 2022. All Rights Reserved.